ClinicalTrials.gg
CompletedNCT05964088Updated Jul 27, 2023

Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients

An observational study in Acute Kidney Injury, sponsored by Arrowhead Regional Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Arrowhead Regional Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
267
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Enrollment
52nd of 131
267 · median 124
Started
2020
with 29 others
Observational
132 of 370
21 open now
Registered
298th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 52nd largest by enrollment of the 131 observational ones that give a count, is one of 30 that started in 2020, is one of 132 observational ones, and was the 298th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

This study explored the incidence of morbidity and mortality associated with AKI in critically ill adult patients infected with COVID-19. There are two groups for comparison. Group1. patients were directly admitted to the intensive care unit (ICU) from the emergency department (ED) Group 2. patients were initially managed on the medical floor and later transferred to the ICU for worsening respiratory status. The investigating team evaluated the correlation of inflammatory markers and common risk factors such as obesity, diabetes, hypertension and ethnicity to the development of AKI in the target population. The primary outcome is mortality participants will received their regular healthcare in a medical setting

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a two-year retrospective study of critically ill adult patients infected with COVID-19 that were admitted to the intensive care unit on ventilatory support. Patients included in this study were admitted to Arrowhead Regional Medical Center (ARMC) from March 1, 2020 to February 12, 2022.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

positive for SARS-CoV-2 on a real-time polymerase chain reaction test (RT-PCR) upon admission to the hospital

Exclusion criteria

Exclusion Criteria:

chronic kidney disease end stage renal disease

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
267 participants (actual)
Patient registry
No

Groups and cohorts

  • Group1

    These critically ill patients were directly admitted to the intensive care unit from the emergency department

  • Group 2

    These critically ill patients were were initially managed on the medical floor and later transferred to the intensive care unit for worsening respiratory status

06

What researchers measure

Primary outcomes

  1. Mortality

    mortality at hospital discharge

    Time frame: from admission until death from any cause, whichever comes first, assessed up to three months

07

Study locations

1 site
  • Arrowhead Regional Medical Center
    Colton, California 92324, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Feb 2022, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Jul 27, 2023
StartActual
Mar 1, 2020
Primary completionActual
Feb 12, 2022
CompletionActual
Feb 12, 2022
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05964088
Lead sponsor
Arrowhead Regional Medical Center
Responsible party
Michael Neeki (Attending Physician, Arrowhead Regional Medical Center) — Principal investigator
First posted
Jul 27, 2023
Start date
Mar 1, 2020
Primary completion
Feb 12, 2022
Completion
Feb 12, 2022
Last update
Jul 27, 2023

Study contacts

Michael M Neeki, DO
principal investigator · Arrowhead Regional Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion